Precision Epigenomics published new clinical validation data showing that EPISEEK significantly outperforms market alternatives across every critical operational and clinical metric.
Public source
Publisher name
Public post
Today, we are proud to share new clinical validation data proving that our EPISEEK test significantly outperforms market alternatives across every critical operational a…
Company
Precision Epigenomics
Advanced Solutions to Early Cancer Diagnostics
- Industry
- Medical and Diagnostic Laboratories
- Location
- Tucson, US
- Company size
- 11–50 employees
About Precision Epigenomics
Advanced Solutions to Early Cancer Diagnostics
See moreLatest activity
Latest activity from Precision Epigenomics
7 signals
Research & Knowledge
Precision Epigenomics released the results of its most recent data on the EPISEEK multi-cancer early detection test.
Presence & Recognition
Precision Epigenomics honors all First Responders at the FRI 2026 event.
Research & Knowledge
Precision Epigenomics published the results of a new study showing EPISEEK outperforms alternative liquid biopsy tests across the board in sensitivity, specificity, and turnaround time.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Biocartis
Biocartis published a study in the International Journal of Molecular Sciences testing the Idylla IDH1-2 assay across 106 patient samples spanning glioma, cholangiocarcinoma, chondrosarcoma, breast cancer, and acute myeloid leukemia.
Research & Knowledge
Break Through Cancer
Break Through Cancer published a study in PNAS by the Eradicating Measurable Residual Disease in AML TeamLab team developing a personalized blood test that tracks up to 96 mutations specific to an individual patient’s leukemia.
Research & Knowledge
Helio Genomics
Helio Genomics published results from a prospective, blinded, multicenter CLiMB study demonstrating that HelioLiver blood-based test showed higher sensitivity for hepatocellular carcinoma detection than ultrasound at 47.8% vs. 28.3%
Research & Knowledge
Mercy BioAnalytics, Inc.
Mercy BioAnalytics, Inc. published a peer-reviewed publication in Gynecologic Oncology demonstrating the potential of their EVP-based blood test to detect early-stage high-grade serous ovarian cancer with 89% sensitivity and 98% specificity in preclinical UKCTOCS samples.
Research & Knowledge
Astrin Biosciences